Dynasore: Precision Dynamin GTPase Inhibitor for Endocytosis Research

Executive Summary: Dynasore is a cell-permeable, noncompetitive inhibitor of dynamin GTPase activity with an IC₅₀ of 15 µM, enabling the reversible inhibition of dynamin-dependent endocytosis in mammalian cells (APExBIO). It targets dynamin1, dynamin2, and Drp1, which are essential for GTP binding/hydrolysis and vesicle formation (Zheng et al. 2024). Dynasore's solubility in DMSO and stable storage at -20°C allow reliable experimental handling. Its use extends to models of cancer, neurodegenerative disease, and host-microbiome signaling, as it blocks transferrin and synaptic vesicle uptake (see related article). Rigorous application and clear boundaries make it a gold standard for vesicle trafficking and endocytosis research.

Biological Rationale

Dynamins are large GTPases critical for membrane fission during endocytosis and organelle division. Their GTP hydrolysis activity drives the scission of budding vesicles from plasma and organelle membranes. Regulation of dynamin-dependent endocytosis underpins key biological processes: receptor-mediated uptake, synaptic vesicle recycling, and signal transduction. Disruptions in these pathways are implicated in cancer, neurodegenerative diseases, and microbiome-host interactions (Zheng et al., 2024).

In colorectal cancer, for example, vesicle trafficking modulates tumor-immune responses and the colonization of bacteria such as Fusobacterium nucleatum. Extracellular vesicles shed by bacteria can fuse with host cells and alter their surface properties, facilitating microbial adhesion and pathogenesis (Zheng et al., 2024). Tools that precisely dissect dynamin-mediated vesicle formation are essential for understanding these complex processes.

Mechanism of Action of Dynasore

Dynasore (SKU A1605, APExBIO) is a noncompetitive inhibitor of the GTPase activity of dynamin isoforms 1 and 2, and Drp1. It does not compete with GTP for binding but allosterically blocks the hydrolysis reaction needed for vesicle scission (contrast: rapid vs. classic inhibitors). This leads to a rapid and reversible inhibition of endocytosis within minutes of administration. The compound is cell-permeable and effective in diverse cell lines, including HL-1 cardiomyocytes and primary neurons. The canonical IC₅₀ value for dynamin inhibition is 15 µM under in vitro conditions (pH 7.4, 37°C).

Dynasore’s action is best characterized by its ability to block transferrin uptake, a classic readout for clathrin-mediated endocytosis. This effect is reversed upon compound washout, demonstrating reversibility and suitability for time-resolved studies. Dynasore does not affect dynamin protein expression or other unrelated GTPases at recommended concentrations.

Evidence & Benchmarks

• Dynasore inhibits dynamin GTPase activity with an IC₅₀ of 15 µM in cell-free assays (APExBIO, product data).
• It blocks dynamin-dependent endocytosis in HL-1 cells and neurons, halting transferrin and synaptic vesicle uptake (related discussion).
• Dynasore is soluble in DMSO at ≥16.12 mg/mL, but insoluble in water or ethanol (APExBIO, specification).
• In colorectal cancer models, vesicle trafficking perturbation (including dynamin inhibition) modulates tumor colonization by F. nucleatum (Zheng et al., 2024).
• Dynasore’s reversible inhibition supports dynamic endocytosis studies, unlike covalent or irreversible GTPase inhibitors (see also).

Applications, Limits & Misconceptions

Dynasore is used extensively for:

• Dissecting clathrin- and caveolin-mediated endocytosis in mammalian cells.
• Studying vesicle trafficking and signal transduction in cancer and neurodegenerative disease models.
• Probing the impact of endocytosis on host-microbiome interactions, including tumor colonization by bacterial EVs (Zheng et al., 2024).
• Optimizing high-throughput screens for endocytic pathway modulators (extension: workflow automation).

Common Pitfalls or Misconceptions

• Dynasore does not inhibit endocytosis independently of dynamin: In dynamin knockout or mutant cells, Dynasore does not block vesicle trafficking.
• Limited cell permeability at low DMSO: Stock solutions must be prepared in DMSO and warmed or sonicated to achieve effective concentrations.
• No direct effect on unrelated GTPases: Dynasore’s selectivity is restricted to dynamin1/2 and Drp1 at standard doses.
• Not suitable for diagnostic or therapeutic use: As specified by APExBIO, this reagent is for research use only.
• Solubility limits: Dynasore is not soluble in water or ethanol; incorrect vehicle can lead to precipitation and variable results.

Workflow Integration & Parameters

For optimal results, Dynasore should be dissolved in DMSO at ≥16.12 mg/mL, then diluted into cell culture media immediately before use. The recommended working concentration for most cell-based assays is 10–80 µM, depending on cell type and desired inhibition depth. Stock solutions should be stored at -20°C, protected from light, and can remain stable for several months (see A1605 kit).

Experimental controls should include vehicle-only (DMSO) and washout conditions to confirm reversibility. For studies involving endocytic flux or vesicle trafficking, time-resolved sampling post-addition and post-washout is advised. Protocol adaptations for high-throughput screening are detailed in Dynasore: A Noncompetitive Dynamin GTPase Inhibitor for Endocytosis—this article updates those protocols with new stability data.

Conclusion & Outlook

Dynasore is a robust, noncompetitive dynamin GTPase inhibitor with proven utility in mechanistic studies of endocytosis, vesicle trafficking, and signal transduction. Its rapid onset, reversibility, and high specificity underpin its adoption in cancer, neuroscience, and microbiome research. APExBIO’s Dynasore (A1605) provides a validated, batch-traceable reagent for high-impact studies. Future research will likely integrate Dynasore-based perturbations with single-vesicle imaging, omics, and organoid models for deeper insights into membrane trafficking and disease. This article extends prior reviews by systematically mapping Dynasore’s role in emerging disease models and clarifying its boundaries in experimental use (see contrast: tumor-microbiome signaling).